26.2% vs 32.6%; P = 0.15). Overall and clinical success at EOT were significantly higher for possible IMD compared with proven/probable IMD (48.2% vs 36.2%; P = 0.01, 75.0% vs 63.1%; P = 0.01 respectively). Fewer drug-related TEAEs were reported with isavuconazole compared with voriconazole in patients with either
| INTRODUC TI ON
Invasive mould disease (IMD) remains an important contributor to morbidity and mortality, especially in patients with haematological malignancies and in recipients of allogeneic haematopoietic stem cell transplant and solid organ transplant. [1] [2] [3] [4] Invasive aspergillosis (IA)
is one of the most prevalent IMDs observed among immunocompromised individuals. [5] [6] [7] Treatment guidelines have recommended voriconazole for primary treatment of proven and probable IA and included liposomal amphotericin B as an alternative. [8] [9] [10] However, they are each associated with limitations relating to solubility, bioavailability, and/or tolerability. [11] [12] [13] The more recent guidelines also include recommendations for isavuconazole as primary treatment of IA. 8, 10 Isavuconazole is the active moiety of the water-soluble prodrug isavuconazonium sulphate and has recently been approved as first-line treatment for IA. In the Phase III SECURE trial that compared isavuconazole and voriconazole for the treatment of IMD caused by Aspergillus spp. and other filamentous fungi, isavuconazole demonstrated non-inferior efficacy and was associated with fewer drug-related adverse events and treatment discontinuations. 14 In addition, isavuconazole has shown linear pharmacokinetics (up to 600 mg), high oral bioavailability, no food effect, a lower potential for drug-drug interactions with substrates metabolised by CYP3A4/5, and is available in a cyclodextrin-free intravenous (IV) formulation. 15, 16 Isavuconazole also has demonstrated efficacy in the treatment of mucormycosis 17 and evidence of activity against a variety of other rare fungal spp. and mixed fungal infections. [18] [19] [20] [21] In 2008 excluded from analyses of proven/probable IA. 23 Meanwhile, detection of GM in BAL fluid in combination with suggestive radiological features is the current standard of practice to diagnose IA.
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Post hoc analyses of two previous clinical trials initially conducted more than 10 years ago have noted higher rates of treatment success in patients with possible IMD compared with proven or probable IA using the newer criteria, suggesting that possible IMD might represent diagnosis at an earlier phase of disease. 24, 25 To determine whether those findings were confirmed in a more contemporary large randomised controlled study in IMD, a post hoc analysis of outcomes in patients in the SECURE trial with possible IMD vs patients with proven and probable IMD using the 2008 EORTC/ MSG consensus criteria was performed including the criteria for GM in BAL, which was not included in the original SECURE trial disease categorisation criteria.
| MATERIAL S AND ME THODS

| Study design
Detailed methods and results of the SECURE trial (ClinicalTrials.
gov: NCT00412893) have been previously described. as TEAEs assessed by the study site investigator as remotely, possibly or probably related to study medication.
| Classification
In the SECURE trial, 14 This allowed better comparability to previous studies using the same criteria.
24,25
| Outcomes
In this analysis, treatment efficacy was assessed in groups of patients with possible vs probable/proven IMD using the primary and key secondary outcomes from the parent study (ACM at days 42 and 84, and clinical and overall responses at EOT). Clinical success was defined as complete or partial resolution of attributable clinical symptoms or physical findings. An overall successful response was defined as a complete or partial response to treatment. Safety was assessed by examining the incidence of study drug-related TEAEs in each group (TEAEs assessed by the study site investigator as remotely, possibly, or probably related to study medication). In the parent SECURE trial, treatment-related differences were observed for study drug-related TEAEs and TEAEs in the system organ classes of hepatobiliary, eye, skin and subcutaneous, cardiac and psychiatric disorders, and so these TEAEs also were compared between patients with proven/probable or possible IMD patients. For overall assessment of possible vs probable/proven IMD, treatment groups were pooled to increase the power to detect differences (isavuconazole + voriconazole). Treatment groups were also analysed separately to assess potential treatment differences (isavuconazole vs voriconazole).
| Meta-analysis
To assess the outcomes of this study in the context of published interventional clinical trials, a literature search was performed in PubMed (search criterion: "invasive fungal disease"; filtered by article type "clinical trial") to identify prior studies investigating pharmacological interventions that provided information of proven/ probable vs possible IMD with more than 100 patients in each group.
A meta-analysis was performed to estimate the summary effects of treatment by the calculated difference with 95% confidence interval (CI). A random-effects model was used in this meta-analysis because of anticipated heterogeneity (NCSS 9 Statistical Software [2013] .
NCSS, LLC. Kaysville, UT, USA).
| Statistical analyses
Demographics and baseline characteristics were summarised using descriptive statistics. The P values for differences between patients with proven or probable IMD vs possible IMD in the pooled treatment analyses were calculated using Chi-squares. For analysis of treatment differences, adjusted treatment differences in the success rates (isavuconazole-voriconazole) were calculated by a stratified Cochran-Mantel-Haenszel method. The 95%CI was based on a normal approximation. The stratification was based on geographical region, allogeneic HSCT status, and uncontrolled malignancy. All analyses were performed using SAS 9.3.
| RE SULTS
| Study population
Among the 516 patients from the intent-to-treat population of the SECURE trial, 468 were included in these analyses. Forty-eight patients were considered by the DRC as having insufficient evidence of IMD and were classified as "no IMD"; these patients were not included in this analysis. Based on the 2008 EORTC/MSG criteria, the analyses presented here included 304 patients with proven or probable IMD (isavuconazole group, n = 164; voriconazole group, n = 140
[P = n.s.]) and 164 patients with possible IMD (isavuconazole group, n = 67; voriconazole group, n = 97 [P < 0.01]; Table 1 ).
Baseline characteristics were mostly similar between patients treated with either isavuconazole or voriconazole ( Table 1 ). The most frequent risk factor for IMD was haematological malignancy and uncontrolled malignancy, followed by neutropenia and prior allogeneic HSCT. Lower respiratory tract disease (LRTD) was predominant in both isavuconazole-and voriconazole-treated patients. In comparing the proven/probable IMD vs the possible IMD groups, a greater proportion with proven/probable IMD were Asian, were using corticosteroids, and had non-LRTD, whereas a greater proportion of those with possible IMD had haematological malignancies, uncontrolled malignancies and were neutropenic ( Table 1 ). The mean treatment duration was similar for all groups.
| Efficacy outcomes
For the pooled treatment groups, Kaplan-Meier analysis of day 42 and day 84 ACM are shown in Figure 1 (day 42 P = 0.266, day 84 P = 0.152). Overall and clinical success rates at EOT were significantly higher for patients with possible IMD compared with patients with proven/probable IMD ( Table 2 ). ACM at day 42 and day 84, as well as clinical and overall success rates at EOT were similar between isavuconazole-and voriconazole-treated patients in both subgroups (Table 3) . /L for >10 days at baseline. d One patient in the isavuconazole treatment group was identified by the DRC as having a probable IFD on the basis of adequate host factors, adequate clinical and radiological features and the mycological criterion of nonsterile cytology, direct microscopy or culture evidence of presence of a species of mould. This patient did not meet the diagnostic criteria by GM and was not included in analyses of the subset of patients with probable invasive aspergillosis by serum GM.
TA B L E 1 Demographics and baseline characteristics
| Meta-analysis
A literature search in PubMed identified two additional studies that compared different pharmacological interventions in patients with proven/probable vs possible IMD with more than 100 patients in each group and that reported overall success endpoints using simi- 4.1%-16.8%; Figure 2 ). In addition, ACM was consistently lower in all studies in patients with possible vs proven/probable IMD (Table 4) . A numeric summary of this meta-analysis using Random Effects Model is shown in Table S1 .
| Safety
Overall, TEAEs were reported in most patients in the isavuconazole and voriconazole groups for both possible and proven/probable IMD (Table 5 ). Among patients with proven/probable IMD, significantly fewer study drug-related TEAEs were reported in the isavuconazole group compared with the voriconazole group, whereas similar differences between treatment groups did not reach significance for study drug-related TEAEs in those with possible IMD and for TEAEs leading to permanent discontinuation of study drug and serious TEAEs in both the proven/probable and possible IMD groups. For those TEAEs that were reported in a significantly smaller proportion of the isavuconazole group than the voriconazole group in the parent SECURE study (skin and subcutaneous tissue disorders, eye disorders, and hepatobiliary disorders), the difference remained significant for eye disorders in patients with proven/probable IMD and for skin and subcutaneous tissue disorders as well as hepatobiliary disorders in patients with possible IMD, whereas similar trends in all other groups did not reach significance.
| D ISCUSS I ON
This post hoc analysis shows that, when pooled treatment groups TEAEs between treatment groups in both the possible and proven/ probable IMD categories was also similar to that in the overall study population in the SECURE trial, including the distribution of TEAEs for which treatment-related differences had been observed. Benign, malignant and unspecified (including cysts and polyps).
*P < 0.05.
relevant because most clinicians start antifungal therapy in these suggestive cases.
Although the results of better outcomes associated with possible IMD vs proven/probable IMD are consistent overall with previous analyses, there are important differences. In the post hoc analysis of data from the AmBiLoad trial, the survival rate was significantly higher at 6 weeks in the possible vs the proven/probable group for both the 3 and 10 mg/kg liposomal amphotericin B dose groups, and was also higher at 12 weeks in the 3 mg/kg dose group. 24 Similarly, the reanalysis of the Phase III trial comparing voriconazole with amphotericin B deoxycholate also found a significantly higher survival rate at 12 weeks in patients with possible vs proven/probable IMD in the pooled treatment groups. 25 In the current analysis, the improved survival for the possible vs proven/ probable IMD did not reach significance. However, it is important to note that the original trials that were reanalysed by those inves- 
